Retrospective observational study of patients with atopic dermatitis in remission with Upadacitinib.

Retrospective Observational Study of Atopic Dermatitis Patient After Achieving Remission by Upadacitinib in Japanese Real-world Practice - ROADMAP study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054106

Enrollment

300

Registered

2024-04-12

Start date

2024-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) AD patients receiving upadacitinib for the treatment of AD 2) Patients aged 12 years or older at the start of treatment with Upadacitinib 3) Patients who achieved remission after treatment with Upadacitinib 4) Patients who can be followed up for at least 1 year after remission

Exclusion criteria

Exclusion criteria: 1) Cases of use clearly off-label for Upadacitinib 2) Patients who have requested to refuse to participate in the study

Design outcomes

Primary

Measure	Time frame
Remission maintenance rate at 1 year after achieving remission with Upadacitinib	—

Secondary

Measure	Time frame
Upadacitinib for atopic dermatitis: the actual treatment of atopic dermatitis.	—

Countries

Japan

Contacts

Public ContactRYOICHI TAGUCHI

EBC&M LLC Clinical Division

ryoichi_taguchi@ebc-m.com0364353833

Outcome results